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1. Introduction 
Acquired immune deficiency syndrome (AIDS) has become a global health pandemic and 
the most common cause of death among young adults aged 20-24 years (Patton et al., 2009). 
According to the UN/AIDS Global Report published in November 2010 (UNAIDS 2010), 
about 1.8 million persons died from AIDS-related causes in the year 2009 alone. At the end 
of that year, the epidemic had left behind totally 16.6 million orphans, defined as those 
under 18 who had lost one or both parents to AIDS. Since the beginning of the epidemic, 
nearly 30 million people have died from AIDS-related causes.  
At the end of 2009, an estimated 30.8 million adults and 2.8 million children were living 
with HIV, the human immunodeficiency virus linked to AIDS; with women accounting for 
just over one-half of all adults living with HIV worldwide. During the same year, about 2.6 
million persons became newly infected with HIV, including 370,000 children. Of all people 
living with HIV, about 68% reside in Sub-Saharan Africa (UNAIDS 2010). 
Despite these gruesome statistics, there is no cure in sight. Current treatment is based on the 
use of antiretroviral (ARV) drugs targeted against HIV at various steps in viral replication 
(Sleaseman and Goodenow 2003). Although ARV drugs can reduce viral load in the 
bloodstream, they neither cure HIV infection nor restore the immune system to combat 
AIDS (Roederer 1998, Pakker et al., 1998). Virus is known to persist indefinitely in reservoirs 
of latently-infected cells and emergence of drug-resistant strains is common. Furthermore, 
the effectiveness of ARVs in having any clinical benefits at all depends upon a number of 
factors, particularly the CD4 count and the nutritional status of patients at the point at 
which ARV treatment is commenced (Hong et al., 2001, Paton et al., 2006). Additionally, 
drugs are higly toxic and are often associated with adverse side effects to various organs of 
the body, including the bone marrow and liver, (Fischl et al., 1987, Richman et al., 1987, 
Costello et al., 1988, Abrescia et al., 2008), cellular mitochondria (Carr et al., 2001), and with 
lipodystrophy and dyslipidemia (Carr et al., 1998).   
Consequently, there is need for safe and effective, nontoxic therapy that can not only restore 
the immune system and keep virus multiplication/spread in check but also block AIDS 
progression without harming cells of the host. This review will focus on the relationship of 
nutrition to infection and immunity and evidence from experimental and clinical studies on 
the potential value of micronutrients and their combinations in controlling HIV infection 
and reducing symptoms associated with AIDS. 
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2. Nutritional deficiencies in HIV and AIDS 
The relationship between nutrition, infection and immunity is well established since the 
early 1940’s (Scrimshaw 2003, Webb and Villamor 2007). It is for instance well recognized 
that nutritional deficiency can lower immunity and predispose individuals to microbial 
infection. Conversely, nutritional supplementation can improve immune function and 
prevent/confer resistance to infection. 
As the latent period between HIV infection and AIDS manifestation has been estimated at 8-
10 years (Morgan et al 2002), nutritional cofactors, besides HIV, have been implicated in 
AIDS development (Beach et al., 1992, Baum et al., 1995, Jariwalla et al., 2008a, 2009). 
Furthermore, nutrient supplementation in asymptomatic HIV-infected individuals was 
shown to delay the onset of AIDS (Abrams et al., 1993, Tang et al., 1993), supporting 
involvement of nutritional status as a contributory factor in AIDS development.   
It is universally known since the emergence of the AIDS epidemic in the early 1980’s that 
nutritional deficiencies are prevalent in persons with HIV infection and AIDS (Gray 1984, 
Beach et al., 1992, Jariwalla 1995; see also Table 1). These deficits include: (i) specific 
micronutrient abnormalities such as reduced blood levels of the common ACE vitamins, 
minerals, trace elements including selenium, amino acids such as cysteine, and the tri-peptide 
glutathione, which displays a global systemic deficiency; (ii) macronutrient abnormalities such 
as protein calorie malnutrition, which has been linked to a wasting disease, characteristic of 
AIDS. Malnutrition has also been linked to the spread of AIDS and TB in developing countries 
and with reduced survival (Paton et al., 2006, Turchenko et al., 2008) 
 
MICRONUTRIENT ABNORMALITIES
Vitamins  Trace Elements 
Vitamin A  Selenium 
Vitamin B12  Zinc 
Vitamin B6   
Vitamin C  Amino Acids 
Vitamin E  Cysteine 
  
  Peptides 
  Glutathione 
  
MACRONUTRIENT DEFECITS 
Protein Calorie Malnutrition 
Abnormal Lipids (Dyslipidemia) 
Table 1. Commonly occurring nutritional deficiencies in HIV infection and AIDS 
3. Impact of nutritional deficiencies 
Micronutrient deficiencies in particular vitamin and mineral deficiencies can promote and 
strengthen microbial growth by weakening the immune system of the host, making it prone 
to acquiring new infections (Scrimshaw 2003, Webb and Villamor 2007; see Fig 1). 
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Fig. 1. Impact of micronutrient deficiencies on infectious diseases 
4. Essential role of micronutrients in cell physiology and immunity  
Micronutrients are essential for sustaining all cellular functions including metabolic 
reactions in the cytosol and biochemical functions within cellular organelles (Fig 2). 
Vitamins and minerals are needed in smaller amounts than proteins, fats and sugars but 
without them, cells cannot convert food into biological energy and build different body 
structures. 
 
 
Fig. 2. Micronutrients are essential for sustaining all cellular functions 
Micronutrients are also critical for optimum functioning of the immune system including 
cell-mediated immunity, antibody production (humoral immunity) and optimum thymus 
function (Fig. 3). 
The pathological basis of AIDS is a dysfunctional immune system clinically indicated by 
abnormally low levels of white blood cells. Micronutrients are essential for blood formation, 
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including white blood cells. Of particular importance are: vitamin B-3, vitamin B-5, vitamin 
B-6, vitamin B-12, vitamin C, folic acid and iron. Any textbook of biology or biochemistry 
documents these scientific facts. Moreover, no less than nine Nobel Prizes in Medicine have 
been awarded to date on the discovery of the health benefits of vitamins, relevant to their 
role in cellular physiology and impact on the immune system (Nobel Prize Committee 
website, Nobelprize.org). 
 
 
Fig. 3. Nutrients are critical for optimum immune defense of a host 
5. Role of micronutrients in suppression of virus infection 
Additionally, experimental studies have shown that specific micronutrients can suppress 
virus infection at various steps in the viral life cycle that include blocking (a) virus entry, (b) 
virus multiplication, (c) virus activation in latently infected cells and (d) virus spread (Fig 4). 
Prevent viral entry into cells (Vitamin C, EGCG) 
Stop viral multiplication (Vitamin C, N-Acetylcysteine) 
Prevent activation of “silent” viruses (Vitamin C) 
Limit spread of infections (Lysine, Vitamin C) 
In the case of HIV, micronutrients have been shown to block virus expression at all stages of 
virus-host interactions, which include acute infection, chronic expression and activation 
from latently infected cells (Fig 5). The specific micronutrients demonstrated to affect 
different phases of virus infection are listed in Table 2. Most of them are reducing agents 
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with antioxidant properties. They include: vitamins C and E, amino acid thiols such as 
cysteine or its derivative N-acetyl cysteine (NAC), disulfides such as alpha-lipoic acid, 
tripeptides such as glutathione and its derivative glutathione monoester, polyphenols such 
as epigallo-catecheine gallate (EGCG from green tea) and the trace element selenium. 
Among them, ascorbic acid (vitamin C or ascorbate) is the most versatile, capable of 
blocking HIV replication in all phases of HIV infection namely, acute, chronic and latent 
infection (Harakeh et al., 1990; Harakeh and Jariwalla, 1991, 1995). Cysteine and glutathione 
monoester inhibit chronic HIV expression (Mihm et al., 1991; Kalebic et al., 1991) whereas 
NAC and selenium are effective in inhibiting HIV activation in latently-infected cells 
(Roederer et al., 1990, Harakeh and Jariwalla 1991; Sappey et al., 1994). It has been reported 
that alpha-lipoic acid can block acute infection (Bauer et al., 1991) and flavonoids including 
the polyphenol EGCG inhibit HIV at an early stage, blocking interaction of the virus with  
 
 
Fig. 4. Nutrients can directly suppress viral infections 
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host-cells receptor (Mahmood et al., 1993, Fassina et al., 2002). More recently, green tea 
extract enriched in such polyphenols (80% by weight) was shown to suppress HIV 
production in chronically and latently infected cells (Jariwalla et al., 2010). 
 
 
Fig. 5. Micronutrients can target different stages in HIV-host cell interaction 
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Nutrient Inhibitory Effect Targeted at Reference 
Vitamin E Latent infection Suzuki et al 1993 
Vitamin C 
Acute, chronic and latent 
infection 
Harakeh and Jariwalla (1991, 
1995) 
Cysteine, alpha-lipoic 
acid 
Chronic and acute infection Mihm et al 1991, Baur et al 1991 
NAC, Selenium Chronic and latent infection 
Roederer et al 1990, Harakeh & 
Jariwalla 1991, Sappey et al 
1994. 
Glutathione 
monoester 
Chronic infection Kalebic et al 1991 
Flavonoids, EGCG, 
green tea extract 
Acute infection 
Mahmood et al 1993, Fassina et 
al 2002, Jariwalla et al 2010 
Nutrient mixture 
(NM)* 
Synergistic HIV suppression in 
chronic and latent infection 
Jariwalla et al 2010 
Table 2. Action of micronutrients on phases of HIV infection 
* containing (vitamin C, green tea extract, lysine, proline, arginine, NAC, selenium) 
6. Our approach to controlling virus infection with nutrient synergy 
Although specific, single nutrients have been shown to suppress HIV in previous studies, 
little attention has been directed at blocking virus expression with nutrient combinations. To 
investigate this, we have utilized the principle of nutrient synergy i.e. use of nutrients in 
combination at low to moderate (physiological) levels for prevention and control of disease 
(Rath and Niedzwiecki 1996, Rath et al., 2005, Jariwalla et al., 2008a, 2009). The principle 
underlying nutrient synergy is that nutrients work in the body in harmonious synergy, not 
isolation, and they allow for maximal benefits when used in combination at physiological 
doses. In nutrient synergy 1 + 1 is more than 2 (Fig 6). We have applied this principle to both 
experimental studies of HIV infection as well as the in vivo evaluation of a defined multi-
micronutrient supplement in AIDS patients in a community wide setting. 
 
 
Fig. 6. The benefits of nutrient synergy 
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All nutrients work in our bodies in harmonious synergy, not in isolation. 
Nutrient Synergy allows for achieving maximum health benefits and keeping cellular 
processes in balance using smaller quantities of nutrients. Use of single vitamins in very 
high-doses or a randomly selected nutrient combination is not recommended as an optimal 
approach to health. 
7. Experimental studies in HIV infection  
Studies conducted by us of micronutrient combinations in laboratory cultures of HIV infected 
cells have provided further support for nutritional efficacy in viral immunodeficiency disease 
(Jariwalla et al., 2010). In these studies, we compared the ability of micronutrient combinations 
to single nutrients in the suppression of HIV replication in both chronically and latently 
infected cells. H9-HTLV IIIB is a model, chronically-infected T lymphocytic cell line that 
constitutively produces HIV cytopathic virus in the cell culture supernatant (Popovic et al., 
1984, Gallo et al., 1984, Harakeh et al., 1990, Harakeh and Jariwalla 1991). Exposure of these 
cells to low/moderate concentrations of single micronutrients such as ascorbic acid, green tea 
extract and the amino acids such lysine produced only small inhibitory effects on virus 
production. In contrast, exposure of cells to combinations of micronutrients conferred 
significantly greater HIV suppression compared to single nutrients, indicating a synergistic 
effect. A nutritional mixture (NM), consisting of vitamin C, green tea extract, amino acids 
(lysine, proline, arginine), NAC and selenium also gave enhanced suppression of HIV 
production in this cell line compared to single nutrients (Jariwalla et al., 2010; see also Table 2). 
A similar inhibitory effect on cytokine-stimulated virus expression was obtained in latently 
infected T cells, indicating that micronutrients cooperate to suppress virus expression in both 
chronically and latently-stimulated cells (Jariwalla et al., 2010; Table 2). 
8. Clinical nutrition studies in AIDS patients 
Based on the above scientific evidence of micronutrient effectiveness in laboratory cultures 
of virally-infected cells, we have incorporated the use of micronutrients in natural control of 
HIV infection. Our studies conducted in persons with AIDS symptoms have provided 
further support for micronutrient efficacy in viral immunodeficiency disease (Jariwalla et al., 
2008a, 2009). This in vivo confirmation of micronutrient efficacy was demonstrated in AIDS 
patients in a community wide program conducted in South Africa between 2005 and 2008. 
In this community program, the Dr. Rath Foundation donated a micronutrient supplement 
to the South African National Civic Organization (SANCO) who distributed it among 
people affected by AIDS in various townships in South Africa. 
The micronutrient supplement contained vitamins and trace elements (except iron) that are 
known to modulate the immune system (listed in Fig. 3) plus selenium, essential minerals 
and other important nutrients such as amino acids, green tea extract, bioflavonoids, N-acetyl 
cysteine, inositol and coenzyme Q10. This supplement was given to subjects to be taken 3 
times a day with meals. The characteristics of participants, patient selection, informed 
consent, administration of questionnaire grading AIDS-defining symptoms and the 
evaluation methodology were reported previously (Jariwalla et al., 2008a, 2009). 
The first township where a pilot nutritional program was evaluated was Khayelitsha, a 
township near Cape Town (Jariwalla et al., 2008a). In this pilot protocol, 56 AIDS patients 
completed all 3 examinations and their completed questionnaires were evaluated for 
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changes in severity of symptoms seen after the first 3 visits (8-12) weeks from the beginning 
of micronutrient supplementation. Table 3 lists the AIDS-defining symptoms for Africa, 
other physical symptoms, pain symptoms and symptoms of well-being. Tables 4-6 show a 
summary of the impact on these symptoms from micronutrient supplementation. The 
results showed that within 10-12 weeks, the micronutrient supplement statistically 
significantly suppressed all AIDS-defining symptoms compared to baseline. The 
supplement also significantly suppressed other physical symptoms frequently seen in AIDS 
patients including state of well-being (Jariwalla et al., 2008a). 
 
AIDS-Defining Symptoms Symptoms of Well Being
Fever Appetite 
Diarrhoea Energy 
Cough Enjoyment of life 
Weight loss Fear of future 
TB Concentration 
Oppurtunistic infections Anxiety 
Depression 
Other Physical Symptoms Insomnia 
Swollen glands Fatigue 
Colds, flu 
Rashes 
Wounds, sores, ulcers 
Headache 
Bloating, gas 
Other physical symptoms 
Table 3. AIDS-Related Symptoms, Conditions and Diseases Monitored in  Community Wide 
Micronutrient Program 
The micronutrient supplement evaluated in Khayelitsha was also rolled out in KwaZulu 
Natal district (near Durban) where a very large group (522 patients) completed all 3 exams 
and questionnaires. Similar to Khayelitsha, the same trend in reduction of AIDS-defining 
symptoms, other physical AIDS-associated symptoms and pain symptoms was seen (Tables 
4-6). The results were also confirmed in two other townships (Western Cape and Free State), 
for a total of 813 participants from all 4 townships (Tables 4-6). 
 
Site 
Total no of 
patients 
% decrease in AIDS-defining symptoms from 
baseline after 3 visits * 
Khayelitsha 50 33-61% 
Kwazulu-Natal (KZN) 473 37-48% 
Western Cape 153 51-78% 
Free State 82 23-26% 
Table 4. Impact of micronutrient supplementation on AIDS defining symptom in a 
community wide program 
*8-12 weeks except Free State (= 40 weeks) 
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Site 
Total no of 
patients 
% decrease in other physical symptoms from 
baseline after 3 visits * 
Khayelitsha 45 37-60% 
Kwazulu-Natal (KZN) 522 17-54% 
Western Cape 153 44-83% 
Free State 78 17-47% 
Table 5. Impact of micronutrient supplementation on other physical symptoms in AIDS 
patients in community wide program 
* 8-12 weeks except Free State (= 40 weeks) 
 
 
Site 
Total no of 
patients 
% decrease in pain symptoms from 
baseline after 3 visits * 
Khayelitsha 44 38-49% 
Kwazulu-Natal (KZN) 511 32-50% 
Western Cape 149 43-64% 
Free State 79 24-35% 
Table 6. Impact of micronutrient supplementation on pain symptoms in AIDS patients in 
community wide program  
* 8-12 weeks except Free State (= 40 weeks) 
9. Conclusion 
The results we have seen are not in isolation. Beneficial effects of micronutrients and their 
combinations have been seen in clinical studies conducted by other researchers as 
summarized in Table 7. These studies have evaluated nutrients in combination and reported 
beneficial effects on various outcomes including improvement in viral and immune 
parameters, antioxidant protection from cellular damage, slowing of disease progression, 
reduction of AIDS-related symptoms and improvement of birth outcomes in pregnant 
women. The impact of nutritional support and vitamin and micronutrient supplementation 
in the treatment of HIV and AIDS is a seriously under-investigated area. Repeated calls have 
been made for more studies in this area by international health agencies. Although 
micronutrients are not a cure for AIDS, in the absence of an effective cure or vaccine and in 
the face of the toxicity and limited efficacy of ARVs, they are a safe, effective and affordable 
way to halt progression towards and even reduce the symptoms of the AIDS disease and to 
improve the quality of life of AIDS patients.  
The implications of micronutrient supplementation results for public health and control of 
infectious and immunodeficiency disease are enormous. If properly evaluated, 
micronutrients have the potential of being incorporated into strategies for fighting viral 
pandemics on a global scale. Implementation of the above positive findings could save 
millions of lives. 
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Micronutrient Supplement Clinical change Reference 
Multivitamin Supplement 
Delayed onset of AIDS in HIV 
positive   asymptomatic persons
Abrams et al 1993, Tang  
et al 1993
N-acetylcysteine (NAC) 
Increased survival compared to 
placebo
Herzenberg et al 1997 
Vitamin C plus E 
1) Reduced oxidative stress, viral 
load     2) Prevention of AZT-induced 
miochondrial damage
Allard et al 1998, de la 
Asuncion et al 1998 
NAC plus vitamin C 
Enhanced immune responses and 
reduced viral load in advanced AIDS
Muller et al 2000 
Multivitamin Supplement 
Reduced fetal death among HIV-
infected Tanzanian women
Fawzi et al 1998, 2004 
Multi-micronutrient 
Supplement
Increased survival among HIV-
infected persons in Bangkok
Jiamton et al 2003 
Micronutrient Supplement Improved CD4 count Kaiser et al 2006 
Nutritional Supplements 
Delayed AIDS progression in HIV-
infected persons
Namulemia et al 2007 
Alpha-lipoic acid 
Enhanced blood glutathione and 
improved lymphocyte function
Jariwalla et al 2008b 
Micronutrient Supplement 
(see text, page 8) 
Reduced AIDS related and pain 
symptoms; improved state of well 
being
Jariwalla et al 2008a; 
2009 
Table 7. Clinical improvements seen upon micronutrient supplementation in HIV and AIDS 
patients, in peer-reviewed published studies. 
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